4-Methylmorpholine → HCID 57440192, Verbindung

HRID 269616Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 269616
[C:1]([O:5][C:6]([NH:8][C@@H:9]([CH2:13][CH2:14][NH:15][C:16]([O:18][C:19]([CH3:22])([CH3:21])[CH3:20])=[O:17])[C:10](O)=[O:11])=[O:7])([CH3:4])([CH3:3])[CH3:2].C1(NC2CCCCC2)CCCCC1.CN1CCOCC1.ClC(OCC)=O.[H-].[Al+3].[Li+].[H-].[H-].[H-]>O1CCCC1>[C:19]([O:18][C:16](=[O:17])[NH:15][CH2:14][CH2:13][C@H:9]([NH:8][C:6]([O:5][C:1]([CH3:4])([CH3:3])[CH3:2])=[O:7])[CH2:10][OH:11])([CH3:22])([CH3:21])[CH3:20]

Komponenten

6

Versuchsvorschrift

Preparation takes place in analogy to Example 83A from 300 mg (0.60 mmol) of (2S)-2,4-bis[(tert-butoxycarbonyl)amino]butanoic acid-N-cyclohexylcyclohexanamine (1:1) in 10 ml of tetrahydrofuran with 61 mg (0.60 mmol) of 4-methylmorpholine, 65 mg (0.60 mmol) of ethyl chloroformate and 1.2 ml (1.20 mmol) of a 1M solution of lithium aluminum hydride in tetrahydrofuran. The product is reacted without further purification.

Aufarbeitung

  1. customPreparation
  2. customThe product is reacted without further purification

Quellen und Nachweise

ORD-Eintrag
ord-33e3102543ad476bac7b665f63129af9
Quelldatensatz
uspto-grants-2008_11
Patentnummer
US07446102B2

Notizen zur Reaktion

Wird geladen…